Active-ingredient Dossier
Methylphenidate Hydrochloride
Active-ingredient Dossier for Methylphenidate Hydrochloride (central nervous system stimulant). Australian brands, products, PBS listings, PBAC outcomes…
- Brand: ARTIGE
- Brand: ATENZA XR
- Brand: METHYLPHENIDATE XR ARX
- Brand: RITALIN
- Brand: RUBIFEN LA
- Brand: CONCERTA
- Therapeutic area: Psychiatry
What is
Methylphenidate Hydrochloride Methylphenidate Hydrochloride is a central nervous system stimulant.
Australian brands containing
Methylphenidate Hydrochloride — ARTIGE — ATENZA XR — CONCERTA — METHYLPHENIDATE XR ARX — RITALIN — RUBIFEN LA — RINIDATE — ATTORA LA — METHYLPHENIDATE SANDOZ XR — METHYLPHENIDATE-TEVA XR
Therapeutic areas
Methylphenidate Hydrochloride is registered in Neurology (10 brands) and Psychiatry (3 brands).
Sponsor landscape
The ingredient is marketed by eight sponsors: Arrotex Pharmaceuticals, Novartis Pharmaceuticals, Teva Pharma, Nova Pharmaceuticals, Alphapharm and Janssen-Cilag.
PBS and regulatory activity
Six brands containing Methylphenidate Hydrochloride have PBS-listed items, with the latest PBS schedule dated 1 May 2026. The latest PBAC outcome is from 1 March 2020, with three brands holding PBAC outcomes on record and no AusPARs on record.